Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,849 | 326 | 81.9% |
| Long term medical supply or device loan | $681.53 | 7 | 9.5% |
| Education | $606.93 | 20 | 8.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,163 | 38 | $0 (2024) |
| PFIZER INC. | $629.87 | 55 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $438.66 | 41 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $320.50 | 14 | $0 (2024) |
| Sirtex Medical Inc | $295.82 | 5 | $0 (2024) |
| Genentech USA, Inc. | $275.85 | 16 | $0 (2020) |
| Merck Sharp & Dohme LLC | $247.81 | 15 | $0 (2023) |
| Janssen Biotech, Inc. | $247.51 | 12 | $0 (2024) |
| Incyte Corporation | $224.98 | 7 | $0 (2024) |
| Medtronic, Inc. | $221.36 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,979 | 64 | Novartis Pharmaceuticals Corporation ($743.83) |
| 2023 | $1,371 | 63 | Novartis Pharmaceuticals Corporation ($129.93) |
| 2022 | $485.34 | 25 | Medtronic, Inc. ($91.05) |
| 2021 | $164.11 | 6 | Lilly USA, LLC ($100.39) |
| 2020 | $269.44 | 14 | Genentech USA, Inc. ($58.27) |
| 2019 | $615.89 | 36 | Novartis Pharmaceuticals Corporation ($86.75) |
| 2018 | $869.44 | 75 | PFIZER INC. ($142.41) |
| 2017 | $1,383 | 70 | Sirtex Medical Inc ($240.90) |
All Payment Transactions
353 individual payment records from CMS Open Payments — Page 15 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/10/2017 | EMD Serono, Inc. | XALKORI (Biological) | Food and Beverage | Cash or cash equivalent | $16.41 | General |
| Category: Oncology | ||||||
| 01/06/2017 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $10.79 | General |
| Category: Oncology | ||||||
| 01/03/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.37 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,869 | 94,092 | $5.4M | $1.1M |
| 2022 | 52 | 2,324 | 90,530 | $5.4M | $833,906 |
| 2021 | 51 | 3,166 | 122,423 | $6.4M | $1.1M |
| 2020 | 50 | 3,124 | 127,121 | $6.4M | $1.1M |
All Medicare Procedures & Services
203 procedure records from CMS Medicare Utilization — Page 2 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 82728 | Ferritin (blood protein) level | Office | 2023 | 105 | 171 | $10,260 | $2,285 | 22.3% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 58 | 97 | $9,603 | $1,802 | 18.8% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 27 | 27 | $9,396 | $1,591 | 16.9% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 14 | 826 | $10,738 | $1,496 | 13.9% |
| 83550 | Iron binding capacity | Office | 2023 | 105 | 173 | $6,055 | $1,483 | 24.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 136 | $13,056 | $1,452 | 11.1% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 14 | 89 | $8,366 | $1,326 | 15.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 20 | 202 | $87,062 | $1,318 | 1.5% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 29 | 1,590 | $181,260 | $1,315 | 0.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 14 | 72 | $7,200 | $1,122 | 15.6% |
| 83540 | Iron level | Office | 2023 | 105 | 173 | $4,671 | $1,097 | 23.5% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 12 | 49 | $5,586 | $901.93 | 16.1% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 25 | 97 | $3,298 | $614.98 | 18.6% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 23 | 1,880 | $45,120 | $566.81 | 1.3% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 14 | 19 | $4,693 | $535.04 | 11.4% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 17 | 20 | $2,560 | $407.80 | 15.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 52 | 3,952 | $3,952 | $383.03 | 9.7% |
| 85007 | Microscopic examination for white blood cells with manual cell count | Office | 2023 | 25 | 97 | $2,134 | $360.84 | 16.9% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 12 | 152 | $45,600 | $299.42 | 0.7% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 16 | 29 | $2,175 | $280.14 | 12.9% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 22 | 66 | $1,254 | $131.40 | 10.5% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 29 | 141 | $987.00 | $114.86 | 11.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 13 | 196 | $7,056 | $80.04 | 1.1% |
| J3490 | Unclassified drugs | Office | 2023 | 12 | 52 | $416.00 | $32.69 | 7.9% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 17 | 31 | $589.00 | $30.53 | 5.2% |
About Dr. Akbar Rizvi, MD
Dr. Akbar Rizvi, MD is a Hematology & Oncology healthcare provider based in Mckinney, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1225023948.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Akbar Rizvi, MD has received a total of $7,137 in payments from pharmaceutical and medical device companies, with $1,979 received in 2024. These payments were reported across 353 transactions from 61 companies. The most common payment nature is "Food and Beverage" ($5,849).
As a Medicare-enrolled provider, Rizvi has provided services to 11,483 Medicare beneficiaries, totaling 434,166 services with total Medicare billing of $4.2M. Data is available for 4 years (2020–2023), covering 203 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Mckinney, TX
- Active Since 09/19/2005
- Last Updated 02/04/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1225023948
Products in Payments
- KISQALI (Drug) $753.26
- SIR-Spheres Microspheres (Device) $295.82
- OPDIVO (Biological) $276.47
- KEYTRUDA (Biological) $214.37
- Optune (Device) $201.34
- OSTEOCOOL RF ABLATION SYSTEM (Device) $198.91
- SARCLISA (Biological) $167.51
- BOSULIF (Drug) $158.59
- IBRANCE (Drug) $148.80
- DARZALEX (Biological) $142.87
- IMFINZI (Biological) $137.51
- BESREMI (Drug) $110.77
- ZYTIGA (Drug) $110.65
- XARELTO (Drug) $110.07
- Avastin (Biological) $106.25
- XALKORI (Drug) $105.99
- AFINITOR (Drug) $100.96
- JAKAFI (Drug) $99.57
- LYNPARZA (Drug) $92.81
- ELIQUIS (Drug) $88.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Mckinney
Dr. Sultan Chowdhary, Md, MD
Hematology & Oncology — Payments: $13,456
Dr. Nithya Palanisamy, Md, MD
Hematology & Oncology — Payments: $9,411
Amanullah Khan, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $3,366
Dr. Arisha Patel, Md, Mba, MD, MBA
Hematology & Oncology — Payments: $112.89